Linarin Reverses Doxorubicin Resistance by Modulating PTEN and MDR1 Expression in MCF-7 Breast Cancer Cells

Introduction

Chemoresistance in breast cancer remains a major obstacle that limits the effectiveness of current therapeutic options for patients. Therefore, the identification or development of adjuvant compounds with minimal side effects to enhance the efficacy of standard treatments continues to be an important goal in cancer therapy. In this study, we investigated the impact and molecular mechanisms of linarin to overcome drug resistance in the doxorubicin-resistant MCF-7 breast cancer cell line (MCF-7/DOX).